Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000921895-26-000466·BIOTECHNOLOGY VALUE FUND L P
Schedule 13G ownership disclosure
STRUCTURE THERAPEUTICS INC
Ordinary Shares, par value $0.0001 per share · CUSIP: 86366E106
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- BIOTECHNOLOGY VALUE FUND L P
Shares: 5,583,855.00 · Class: 2.6%
- BVF I GP LLC
Shares: 5,583,855.00 · Class: 2.6%
- BIOTECHNOLOGY VALUE FUND II LP
Shares: 4,053,954.00 · Class: 1.9%
- BVF II GP LLC
Shares: 4,053,954.00 · Class: 1.9%
- Biotechnology Value Trading Fund OS LP
Shares: 643,536.00 · Class: 0.3%
- BVF Partners OS Ltd.
Shares: 643,536.00 · Class: 0.3%
- BVF GP HOLDINGS LLC
Shares: 9,637,809.00 · Class: 4.5%
- BVF PARTNERS L P/IL
Shares: 10,437,066.00 · Class: 4.9%
- BVF INC/IL
Shares: 10,437,066.00 · Class: 4.9%
- LAMPERT MARK N
Shares: 10,437,066.00 · Class: 4.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000921895-26-000466
- Form type
- SCHEDULE 13G/A
- Filer
- BIOTECHNOLOGY VALUE FUND L P
- CIK
- CIK 918923
- Filed
- Feb 17, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership